Lenvatinib acts on platelet‑derived growth factor receptor β to suppress the malignant behaviors of gastric cancer cells.
gastric cancer
lenvatinib
platelet-derived growth factor receptor
tyrosine kinase inhibitor
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
received:
29
03
2024
accepted:
22
07
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
Given the limited treatment options and high mortality rates associated with gastric cancer, there is a need to explore novel therapeutic options. The present study aimed to investigate the efficacy of lenvatinib, a multi-target tyrosine kinase inhibitor, in mitigating the progress of gastric cancer
Identifiants
pubmed: 39170883
doi: 10.3892/ol.2024.14616
pii: OL-28-4-14616
pmc: PMC11338234
doi:
Types de publication
Journal Article
Langues
eng
Pagination
483Informations de copyright
Copyright: © 2024 Tong et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.